Research programme: protein kinase inhibitors - PIQUR Therapeutics

Drug Profile

Research programme: protein kinase inhibitors - PIQUR Therapeutics

Alternative Names: PQR-311; PQR-316; PQR-3xx; PQR-401; PQR-514; PQR-530; PQR-620

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Janus kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain disorders; Eye disorders; Lymphoma; Skin disorders; Solid tumours
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland
  • 01 Apr 2017 Pharmacokinetic data from a preclinical study in Solid tumour presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 08 Feb 2017 Preclinical trials in Solid tumours in Switzerland (unspecified route), before February 2017 (PIQUR Therapeutics pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top